{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 73 of 122', \"control over the subject's peanut allergy and 1 related to perceived confidence in managing\", 'allergic reactions to peanut. Each item is scored on a 4-point scale from 1 to 4, with lower', 'values indicating less control or confidence. The parent/caregiver will complete the', 'parent/caregiver form and subjects aged > 13 years will complete the teenager form.', '9.1.7', 'Global Assessments of HRQOL', 'The parent/caregiver form and teenager form for global assessment of HRQOL each include', \"5 items: 4 items related to the subject's HRQOL (with the same domains as the related\", 'FAQLQ questionnaires) and 1 global HRQOL item. The child form does not include the', 'global HRQOL item. Each item is scored on a 5-point scale from 1 to 5, with lower values', 'indicating better HRQOL. The parent/caregiver will complete the parent/caregiver form,', 'subjects aged > 13 years will complete the teenager form, and subjects aged 8 to 12 years', 'will complete the child form.', '9.1.8 Assessments of Food Challenge Outcomes', 'The parent/caregiver form and patient form for the assessment of food challenge outcomes', \"each include 3 items. The items assess the parent/caregiver and subject's level of\", 'reassurance based on the result of the food challenge, level of worry about future allergic', 'reactions due to accidental peanut exposure based on the result of the food challenge, and', 'rating of severity of the allergic reaction to the food challenge. Each item is scored on a', '4-point scale from 1 to 4, with lower values indicating no reassurance/worry or no reaction.', 'The parent/caregiver will complete the parent/caregiver form and subjects aged > 13 years', 'will complete the patient form.', '9.1.9 TSQM-9 Questionnaire', 'The generic TSQM-9 questionnaire is a 9-item instrument used to evaluate subject treatment', 'satisfaction (Bharmal, 2009). Higher scores indicate greater treatment satisfaction.', '9.1.10 Exit Questionnaire', 'Bespoke exit questionnaires were developed to assess parent/caregiver and subject', 'experience and satisfaction with study treatment. The exit parent/caregiver form includes', 'items related to both parent/caregiver and subject experience with study treatment, and will', 'be completed by the parent/caregiver. The exit patient form includes items related to subject', 'experience with study treatment, and is completed by subjects aged > 13 years.', '9.1.11 Qualitative Exit Interview', 'The qualitative exit interview will follow a semistructured interview guide and explore', 'subject and/or parent/caregiver experience living with peanut allergy before and after AR101', 'treatment, as well as their treatment experience. The duration of the exit interview will be up', 'to 60 minutes. The exit interview will be scheduled as soon as possible after the study exit or', 'early discontinuation visit, at a time convenient for the subject and/or parent/caregiver, and']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 74 of 122', 'may be conducted by telephone. The exit interview will be conducted in a random sample of', 'parents/caregivers and subjects aged > 13 years at study exit or early discontinuation.', '9.2', 'Measures of Desensitization', 'Desensitization will be measured using the SPT, OLFC, and RWPC according to the', 'schedules of activities.', '9.2.1', 'Skin Prick Test', 'Peanut SPT mean wheal diameters will be measured to assess the immunomodulatory effects', 'of AR101 treatment. SPTs for peanut extract will be performed after antihistamines are', 'discontinued for at least 5 half-lives of the medication, according to the schedules of', 'activities. Details are provided in the study manual.', '9.2.2', 'Open-Label Food Challenge', 'Subjects receiving AR101 treatment will have an OLFC after at least 6 months (up to', '7 months) of maintenance treatment with AR101 at 300 mg/day to assess the level of', 'desensitization to peanut protein. Subjects receiving standard of care alone will have an', 'OLFC approximately 12 months after randomization.', 'The OLFC will be conducted within a single day and consistent with accepted food challenge', 'procedures. The OLFC will conditionally test single doses of peanut protein (3, 10, 30, 100,', '300, 600, and 1000 mg) using a food challenge mixture containing defatted peanut flour,', 'administered sequentially at 20- to 30-minute intervals up to a single highest dose of', '1000 mg of peanut protein (2043 mg cumulative). The OLFC is described in detail in', 'Appendix 1, including all requirements before, during, and after the OLFC.', '9.2.3', 'Real-World Peanut Challenge', 'Subjects receiving AR101 treatment who tolerate the 1000 mg (2043 mg cumulative) OLFC', 'dose of peanut protein will have the option to consent for an RWPC under direct observation', 'at the study site within 4 weeks (preferably within 1 week) after the OLFC. The RWPC is', 'described in detail in Appendix 2, including all requirements before, during, and after the', 'RWPC.', '9.3', 'Safety and Other Assessments', '9.3.1', 'Lung Function Tests and Assessments of Asthma Control', 'Lung function tests will be performed according to the schedules of activities. Lung function', 'tests include PEFR for subjects aged > 6 years and attempts of PEFR for subjects aged 4 to', '5 years. Spirometry (FEV1) will be obtained if PEFR shows a clinically relevant reduction or', 'for symptoms of clinical deterioration (eg, active wheeze on physical examination).']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 75 of 122', 'For subjects with asthma, the evaluation of asthma severity will be assessed using the', 'classification in Table 19.', 'Asthma control in subjects with pre-existing asthma will be assessed using scores from the', 'Asthma Control Test (ACT) (Schatz, 2006) and by the incidence of asthma rescue', 'medication use. The ACT is a self-administered, 5-item questionnaire for subjects aged', '> 12 years, used to evaluate the level of asthma control in the last 4 weeks. Each question is', 'presented on a 5-point scale, with lower numbers indicating worse asthma control.', 'A composite score of more than 19 indicates well-controlled asthma.', 'The Childhood Asthma Control Test (C-ACT) is a 7-item questionnaire used to evaluate the', 'level of asthma control in subjects aged 4 to 11 years with pre-existing asthma (Liu, 2007).', 'Subjects complete the first part of the questionnaire, which consists of 4 questions and a', 'choice of 4 responses from 0 (worse asthma) to 3 (controlled asthma) for each question. The', 'parent/caregiver may help the subject read or understand the question if needed, but only the', 'subject should select the response. The parent/caregiver completes the second part of the', 'questionnaire, which consists of 3 questions and a choice of 6 responses from 0 (worse', 'asthma) to 5 (controlled asthma) for each question. Parents/caregivers are asked to recall', 'asthma symptoms in the last 4 weeks and complete their portion of the questionnaire without', \"influence from the subject's responses. A composite score of more than 19 indicates\", 'well-controlled asthma.']", "completion": ""}